The features of tumor niche cell composition in invasive breast ductal carcinoma of no special type

Breast cancer is the most common cancer and the leading cause of cancer death in woman of childbearing age. Tumor progression depends on the character of stromal-parenchymal interactions. Tumor microenvironment exerts a key influence on tumor progression. Tumor niche is an important element of the tumor microenvironment. According to existing ideas, tumor niche consists on immune cells and bone marrow progenitor cells. The present study describes the parameters of tumor niche in invasive breast carcinoma of no special type (IC-NST), associated with lymph node metastases. The purpose of the study was to investigate the features of tumor niche cell composition in IC-NST. Material and methods. The study included 128 patients with IC-NST (T1–3N0–3M0), who underwent total mastectomy or partial mastectomy with axillary lymph node dissection. The age of the patients ranged from 29 to 90. Histological examination of surgical specimens was carried out in accordance with standard methods. Suspensions of fresh frozen tumor surgical specimens were prepared for the hematopoetic progenitor cells identification. The antibodies against CD34, CD133, CD90, CD11B, CD45, AND CD202 were applied. Results. The study showed that the total number of hematopoietic stem and progenitor cells and macrophage progenitor cells in an amount exceeding 1.24 cells per 100 tumor cells was associated with the risk of developing lymph node metastases and large tumor size. Conclusion. The results obtained may be useful for understanding the role of tumor niche in tumor growth and lymph node metastasis of IC-NST.

1. Harbeck N., Gnant M. Breast cancer. Lancet. 2017; 389(10074): 1134–50. doi: 10.1016/S0140-6736(16)31891-8.

2. Kaprin A.D., Aleksandrova L.M., Starinsky V.V., Mamontov A.S. Technologies for early diagnosis and screening in the early detection of malignant neoplasms. P.A. Herzen Journal of Oncology. 2018; 7(1): 34–40. (in Russian). doi: 10.17116/onkolog20187134–40.

3. Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med. 2006; 6(6): 685–93. doi: 10.2174/156652406778195053.

4. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009; 9(4): 285–93. doi: 10.1038/nrc2621.

5. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol. 2014; 4: 62. doi: 10.3389/fonc.2014.00062.

6. Luo H., Tu G., Liu Z., Liu M. Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Lett. 2015; 361(2): 155–63. doi: 10.1016/j.canlet.2015.02.018.

7. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W, Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449(7162): 557–63. doi: 10.1038/nature06188.

8. Sepúlveda P., Martinez-León J., García-Verdugo J.M. Neoangiogenesis with endothelial precursors for the treatment of ischemia. Transplant Proc. 2007; 39(7): 2089–94. doi: 10.1016/j.transproceed.2007.07.009.

9. Timmermans F., Plum J., Yöder M.C., Ingram D.A., Vandekerckhove B., Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med. 2009; 13(1): 87–102. doi: 10.1111/j.1582-4934.2008.00598.x.

10. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66(2): 605–12. doi: 10.1158/0008-5472.CAN-05-4005.

11. Cuiffo B.G., Karnoub A.E. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr. 2012; 6(3): 220–30. doi: 10.4161/cam.20875.

12. Nishimura K., Semba S., Aoyagi K., Sasaki H., Yokozaki H. Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells. Pathobiology. 2012; 79(6): 290–306. doi: 10.1159/000337296.

13. Botelho M.C., Alves H. Endothelial Progenitor Cells in Breast Cancer. Int J Immunother Cancer Res. 2016; 2: 1–2.

14. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P., Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008; 18(5): 349–55. doi: 10.1016/j.semcancer.2008.03.004.

15. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1): 49–61. doi: 10.1016/j.immuni.2014.06.010.

16. Fox J.M., Chamberlain G., Ashton B.A., Middleton J. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol. 2007; 137(6): 491–502. doi: 10.1111/j.1365-2141.2007.06610.x.

17. Oberoi P., Kamenjarin K., Ossa J.F.V., Uherek B., Bönig H., Wels W.S. Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK cells with Enhanced Antitumor Activity. Cells. 2020; 9(4): 811. doi: 10.3390/cells9040811.

18. Jayasingam S.D., Citartan M., Thang T.H., Mat Zin A.A., Ang K.C., Ch’ng E.S. Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice. Front Oncol. 2020; 9: 1512. doi: 10.3389/fonc.2019.01512.

19. Klimek M. Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970-2018. Postgrad Med. 2019; 131(5): 309–18. doi: 10.1080/00325481.2019.1595982.